Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05238337 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of the Absorption, Metabolism, and Excretion of [14C] PBI-200
A Phase 1 study, sponsored by Pyramid Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT05238337 is a Phase 1 study that has completed, run by Pyramid Biosciences. The registered enrollment target is 6 participants.
The verdict
NCT05238337, a Phase 1 study, has completed, sponsored by Pyramid Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label non-randomized, single dose study in healthy male subjects.
Interventions
- DRUG [14C]-PBI-200
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-02-24 |
| Est. Completion | 2022-03-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05238337
The ClinicalTrials.gov registry entry for NCT05238337 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pyramid Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [14C]-PBI-200 is the first listed.
NCT05238337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05238337 about?
NCT05238337 is a clinical study titled "A Phase 1 Study of the Absorption, Metabolism, and Excretion of [14C] PBI-200". This is a Phase 1, open-label non-randomized, single dose study in healthy male subjects.
What is the current status of trial NCT05238337?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2022-02-24. Estimated completion is 2022-03-24.
What interventions are being tested in trial NCT05238337?
The interventions under investigation include: [14C]-PBI-200 (DRUG).
Who is sponsoring clinical trial NCT05238337?
This trial is sponsored by Pyramid Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.